- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06161506
En fas II-studie av elektrisk ytstimulering för urininkontinens hos män som behandlas för prostatacancer
Background:
Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.
Objective:
To see if the Elidah device can reduce urinary incontinence after prostate treatment.
Eligibility:
Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.
Design:
Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.
The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.
Participants will be given an Elidah device and taught how to use it at home.
They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.
Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.
Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.
Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.
Participants will complete 15-minute questionnaires.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Background:
- Urinary incontinence is a common side effect of prostate cancer therapy that can negatively impact the quality of life.
- Standard treatment includes an initial course of pelvic floor muscle exercises followed by surgical therapy if urinary incontinence persists.
- Although pelvic floor muscle exercises can be successful in reducing urinary incontinence, compliance with exercises is poor.
- The Elitone (registered trademark) device was recently cleared by the Food and Drug Administration (FDA) for use in women with stress urinary incontinence. This device provides a surface electrical muscle stimulation device designed to contract the pelvic floor muscles and has been shown to reduce incontinence in women using the product.
- Recently, the electrode component (GelPad) of the device has been adapted for use in men by the manufacturing company, Elidah. The male version of the device is named the Elidah device.
Objective:
-To describe the efficacy of the Elidah device on male urinary incontinence
Eligibility:
-
Participants must be male.
-
Participants must have a history of urinary incontinence for at least 6 months after prostate cancer treatment.
-
Participants must have at least one of the following types of urinary incontinence:
- stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities), or on sneezing or coughing;
- urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.
Design:
- This is a phase II trial testing the efficacy of the Elidah device in people treated for prostate cancer with stress and/or urge urinary incontinence.
- Prior to treatment, participants will undergo baseline assessments including 24-hour pad weight testing and questionnaires relating to incontinence and quality of life.
- Participants will self-administer the Elidah device treatment for 20 minutes per day, 5 days per week during a 6-week period in the at-home environment. Participants will maintain a Daily Log to record usage of the Elidah device, urinary leaks, and use of pads during each week of treatment.
- Following 6 weeks of therapy, participants will undergo re-evaluation of symptoms and urinary incontinence via questionnaires and testing with the 24-hour pad weight test.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Deborah E Citrin, M.D.
- Telefonnummer: (240) 760-6206
- E-post: citrind@mail.nih.gov
Studera Kontakt Backup
- Namn: Debbie-Ann N Nathan, R.N.
- Telefonnummer: (240) 858-3103
- E-post: dnathan@mail.nih.gov
Studieorter
-
-
Maryland
-
Bethesda, Maryland, Förenta staterna, 20892
- Rekrytering
- National Institutes of Health Clinical Center
-
Kontakt:
- National Cancer Institute Referral Office
- Telefonnummer: 888-624-1937
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
-
INCLUSION CRITERIA:
-
Participants must be male.
-
Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.
-
Participants must have at least one of the following types of urinary incontinence:
- stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing
- urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.
-
Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.
-
Participants must be able to read and write in English.
-
Age >= 18 years.
-
Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
-
Ability to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA:
- Change of therapy for prostate cancer planned during the study intervention.
- History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.
- Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (>= 4 UTIs within the 12 months prior to the study treatment initiation).
- History of complete denervation of the pelvic floor.
- Severe obesity (body mass index [BMI] >35).
- Pelvic pain/painful bladder syndrome.
- Metal implant in the abdominal or pelvic area.
- History of chronic cough with ongoing symptoms
- An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.
- History of epilepsy.
- History of underlying neurologic/neuromuscular disorder that could contribute to urinary incontinence.
- Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.
- Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: 1/Elidah Device
Elidah device application. |
The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To describe the efficacy of the Elidah device treatment on male urinary incontinence
Tidsram: Baseline and within 2 weeks after completing treatment
|
Percent decrease in 24-hour pad weight after treatment with the Elidah device. |
Baseline and within 2 weeks after completing treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To assess the safety of the Elidah device in men with urinary incontinence
Tidsram: 3 week visit and end of treatment visit
|
Frequency of adverse events among treated participants and reporting the results, by maximum grade of event and type of toxicity noted. |
3 week visit and end of treatment visit
|
|
To assess alternative measures of efficacy of Elidah device on male urinary incontinence and bother
Tidsram: Baseline and at end of treatment visit
|
Evaluated by the number of pads and number of leaks before and after treatment. The mean of the percent reduction in the number of pads used per day following treatment will be computed along with 95% confidence intervals. |
Baseline and at end of treatment visit
|
|
To assess participant-reported outcomes of Elidah device use for male urinary incontinence
Tidsram: Baseline and at end of treatment visit
|
The proportion of participants for which the I-QoL score improves by 2.5 points or more following six weeks of Elidah device use will be estimated. 95% confidence intervals for this proportion will be constructed. |
Baseline and at end of treatment visit
|
|
To assess treatment compliance with the Elidah device
Tidsram: 3 week visit and end of treatment visit
|
A test of binomial proportions will be performed to assess whether the treatment noncompliance rate is above the unacceptability threshold. |
3 week visit and end of treatment visit
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Deborah E Citrin, M.D., National Cancer Institute (NCI)
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Genitala neoplasmer, manliga
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Genitala sjukdomar, manliga
- Prostatasjukdomar
- Manliga urogenitala sjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Urineringsstörningar
- Symtom i de nedre urinvägarna
- Urologiska manifestationer
- Patologiska tillstånd, tecken och symtom
- Tecken och symtom
- Prostatiska neoplasmer
- Urininkontinens
- Urininkontinens, stress
- Prostatahyperplasi
- Urininkontinens, trängsel
Andra studie-ID-nummer
- 10001713
- 001713-C
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
All IPD recorded in the medical record will be shared with intramural investigators upon request.
Tidsram för IPD-delning
Clinical data available during the study and indefinitely.
Kriterier för IPD Sharing Access
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .